Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.

Mittendorf T, Smith-Palmer J, Timlin L, Happich M, Goodall G

Diabetes, obesity & metabolism3 Sept 2009Cited by 27 (Europe PMC)

PMID19732121DOI10.1111/j.1463-1326.2009.01099.xPepBankPUB-19732121

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In a diabetes simulation, exenatide increased projected life expectancy by 0.016 years versus insulin glargine.
In plain wordsComputer projections gave exenatide longer life expectancy than insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseProjected life expectancy
Study
n: not reported in source
Validated computer simulation model of type 2 diabetes
Comparator
Insulin glargine
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Treatment with exenatide compared with insulin glargine was projected to be associated with improvements in life expectancy of 0.016 years and quality-adjusted life expectancy of 0.280 quality-adjusted life years (QALYs),
1 context sentence(design, population, supporting numbers)
Summary · context
Data from a published randomized controlled trial were used in combination with a published, validated computer simulation model of type 2 diabetes to project clinical and cost outcomes over a time horizon of 10 years.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1973212101
02Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In a diabetes simulation, exenatide increased projected quality-adjusted life expectancy by 0.280 QALYs versus insulin glargine.
In plain wordsComputer projections gave exenatide greater quality-adjusted life expectancy than insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseProjected quality-adjusted life expectancy
Study
n: not reported in source
Validated computer simulation model of type 2 diabetes
Comparator
Insulin glargine
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Treatment with exenatide compared with insulin glargine was projected to be associated with improvements in life expectancy of 0.016 years and quality-adjusted life expectancy of 0.280 quality-adjusted life years (QALYs),
1 context sentence(design, population, supporting numbers)
Summary · context
Data from a published randomized controlled trial were used in combination with a published, validated computer simulation model of type 2 diabetes to project clinical and cost outcomes over a time horizon of 10 years.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1973212102
03Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In a diabetes simulation, exenatide increased projected lifetime direct medical costs versus insulin glargine.
In plain wordsComputer projections gave exenatide higher medical costs than insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseProjected direct medical costs
Study
n: not reported in source
Validated computer simulation model of type 2 diabetes
Comparator
Insulin glargine
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
increased lifetime direct medical costs of euro 3854 (euro 22 095 vs. euro 18 242) and an incremental cost-effectiveness ratio (ICER) of euro 13 746 per QALY.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from a published randomized controlled trial were used in combination with a published, validated computer simulation model of type 2 diabetes to project clinical and cost outcomes over a time horizon of 10 years.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1973212103
04Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In a diabetes simulation, exenatide had an ICER of euro 13 746 per QALY versus insulin glargine.
In plain wordsComputer projections estimated the extra cost per quality-adjusted life year for exenatide versus insulin glargine.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableCost per QALY gained
Study
n: not reported in source
Validated computer simulation model of type 2 diabetes
Comparator
Insulin glargine
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
increased lifetime direct medical costs of euro 3854 (euro 22 095 vs. euro 18 242) and an incremental cost-effectiveness ratio (ICER) of euro 13 746 per QALY.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from a published randomized controlled trial were used in combination with a published, validated computer simulation model of type 2 diabetes to project clinical and cost outcomes over a time horizon of 10 years.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1973212104
05Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
Without quality adjustment, simulated exenatide had an ICER of euro 238 201 per life year gained versus insulin glargine.
In plain wordsComputer projections estimated the extra cost per life year for exenatide versus insulin glargine without quality adjustment.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableCost per life year gained
Study
n: not reported in source
Validated computer simulation model of type 2 diabetes
Comparator
Insulin glargine
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
If quality of life was not taken into account, exenatide was associated with an ICER of euro 238 201 per life year gained vs. insulin glargine.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from a published randomized controlled trial were used in combination with a published, validated computer simulation model of type 2 diabetes to project clinical and cost outcomes over a time horizon of 10 years.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1973212105
06Computer modelNot a test of Exenatide (exendin-4) aloneIn silicoOther
In the diabetes simulation, weight-related utility assumptions and glucose testing rates most strongly affected projected outcomes.
In plain wordsComputer projections were most sensitive to weight-related quality-of-life assumptions and blood glucose testing rates.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableSensitivity of projected outcomes
Study
n: not reported in source
Validated computer simulation model of type 2 diabetes
Comparator
Insulin glargine
Outcome group
Cost-effectiveness · Whole body
Source sentences
Summary
Sensitivity analyses revealed that outcomes were most sensitive to changes in assumptions for (dis)utility values relating to weight change and the rate of self-monitored blood glucose testing.
1 context sentence(design, population, supporting numbers)
Summary · context
Data from a published randomized controlled trial were used in combination with a published, validated computer simulation model of type 2 diabetes to project clinical and cost outcomes over a time horizon of 10 years.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1973212106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.